Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.

1Cancer Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; 2Division of Nuclear Medicine, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah; 3Department of Radiology, University of California, San Francisco, California; 4Division of Nuclear Medicine, Department of Radiology, University of Iowa, Iowa City, Iowa; 5Division of Nuclear Medicine, Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania; 6Department of Nuclear Medicine and PET Research, VU University Medical Centre, Amsterdam, The Netherlands; 7Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York; 8Division of Nuclear Medicine, University of Washington, Seattle, Washington; 9Mallinckrodt Institute of Radiology, St. Louis, Missouri; and 10Department of Radiology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts

[1]  R L Wahl,et al.  Serum glucose: effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-D-glucose in rodents with mammary carcinoma. , 1992, Radiology.

[2]  M. Phelps,et al.  Effects of Temporal Sampling, Glucose Metabolic Rates, and Disruptions of the Blood—Brain Barrier on the FDG Model with and without a Vascular Compartment: Studies in Human Brain Tumors with PET , 1986, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[3]  R L Wahl,et al.  Reevaluation of the standardized uptake value for FDG: variations with body weight and methods for correction. , 1999, Radiology.

[4]  L M Hamberg,et al.  Simplified measurement of deoxyglucose utilization rate. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  R L Wahl,et al.  Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  K Kubota,et al.  From tumor biology to clinical PET: A review of positron emission tomography (PET) in oncology , 2001, Annals of nuclear medicine.

[7]  O. Prante,et al.  Characterization of 18 F-FDG Uptake in Human Endothelial Cells In Vitro , 2004 .

[8]  R. Boellaard,et al.  Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  Stephen L Bacharach,et al.  Simplified kinetic analysis of tumor 18F-FDG uptake: a dynamic approach. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  R L Wahl,et al.  Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET. , 1995, Radiology.

[11]  T. Videen,et al.  Correction for partial volume effects in regional blood flow measurements adjacent to hematomas in humans with intracerebral hemorrhage: implementation and validation. , 1999, Journal of computer assisted tomography.

[12]  G A Ojemann,et al.  Glucose metabolism in human malignant gliomas measured quantitatively with PET, 1-[C-11]glucose and FDG: analysis of the FDG lumped constant. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  A. Alavi,et al.  Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nodules on FDG-PET , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  C S Patlak,et al.  Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data , 1983, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[15]  Paul Kinahan,et al.  SUV varies with time after injection in (18)F-FDG PET of breast cancer: characterization and method to adjust for time differences. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  N. Avril.  GLUT1 expression in tissue and (18)F-FDG uptake. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  M. Baccarani,et al.  18F-FDG PET early after radiotherapy in lymphoma patients. , 2004, Cancer biotherapy & radiopharmaceuticals.

[18]  M. Schwaiger,et al.  Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  M. Graham,et al.  Comparison of simplified quantitative analyses of FDG uptake. , 2000, Nuclear medicine and biology.

[20]  Wolfgang A Weber,et al.  Monitoring response to treatment in patients utilizing PET. , 2005, Radiologic clinics of North America.

[21]  M Schwaiger,et al.  Reproducibility of metabolic measurements in malignant tumors using FDG PET. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  P. V. van Diest,et al.  Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  2-Deoxy-2-[F-18]fluoro-d-glucose-Positron Emission Tomography Sensitivity to Serum Glucose: A Survey and Diagnostic Applications , 2005, Molecular Imaging and Biology.

[24]  S. Libutti,et al.  Comparison of SUV and Patlak slope for monitoring of cancer therapy using serial PET scans , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[25]  Gary T. Smith,et al.  Optimizing imaging time for improved performance in oncology PET studies. , 2002, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[26]  Otto Warburn,et al.  THE METABOLISM OF TUMORS , 1931 .

[27]  C. Patlak,et al.  Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data. Generalizations , 1985, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[28]  G van Kaick,et al.  Glucose uptake, perfusion, and cell proliferation in head and neck tumors: relation of positron emission tomography to flow cytometry. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  P. Plowman.  Stereotactic radiosurgery. VIII. The classification of postradiation reactions. , 1999, British journal of neurosurgery.

[30]  O. Prante,et al.  Characterization of 18F-FDG uptake in human endothelial cells in vitro. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[31]  K. Herholz,et al.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. , 1999, European journal of cancer.

[32]  D. Wood,et al.  Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  Klaus Wienhard,et al.  Measurement of glucose consumption using [(18)F]fluorodeoxyglucose. , 2002, Methods.

[34]  J M Hoffman,et al.  Optimum scanning protocol for FDG-PET evaluation of pulmonary malignancy. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.